<p>Drug firm Zydus Cadila on Tuesday said it has filed the investigational new drug (IND) application for its small molecule candidate ZYIL1, positioned for management of critically ill Covid-19 patients.</p>.<p>"Following up on its initiatives to fight Covid-19 with diagnostics, vaccines and therapeutics, the company is now focussing on cutting edge research to bring targeted therapies...," Zydus Cadila said in a regulatory filing.</p>.<p>The company has filed the IND application of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate, it added.</p>.<p>Zydus Cadila said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including the current pandemic of Covid-19 and address complications caused by chronic and uncontrolled inflammation.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-Covid-19-vaccine-bengaluru-karnataka-mumbai-maharashtra-chennai-tamil-nadu-delhi-kerala-uttar-pradesh-west-bengal-kolkata-cases-deaths-recoveries-health-ministry-910616.html" target="_blank">For live updates of the coronavirus outbreak, click here</a></strong></p>.<p>"We are at the forefront of targeting the innate immune system through novel NLRP3 inflammasome inhibitors candidates with a deep understanding of the inflammasome biology," Cadila Healthcare Chairman Pankaj R Patel said.</p>.<p>ZYIL1 has demonstrated promising efficacy in a number of validated preclinical models of Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS), Sepsis and acute lung injury models of Acute Respiratory Distress Syndrome (ARDS), Zydus Cadila said.</p>.<p>The company has completed all IND enabling preclinical studies and has filed the IND application to advance this drug candidate towards the clinic, it added.</p>.<p>Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 438.60 per scrip on BSE, up 6.94 per cent from its previous close.</p>
<p>Drug firm Zydus Cadila on Tuesday said it has filed the investigational new drug (IND) application for its small molecule candidate ZYIL1, positioned for management of critically ill Covid-19 patients.</p>.<p>"Following up on its initiatives to fight Covid-19 with diagnostics, vaccines and therapeutics, the company is now focussing on cutting edge research to bring targeted therapies...," Zydus Cadila said in a regulatory filing.</p>.<p>The company has filed the IND application of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate, it added.</p>.<p>Zydus Cadila said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including the current pandemic of Covid-19 and address complications caused by chronic and uncontrolled inflammation.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-Covid-19-vaccine-bengaluru-karnataka-mumbai-maharashtra-chennai-tamil-nadu-delhi-kerala-uttar-pradesh-west-bengal-kolkata-cases-deaths-recoveries-health-ministry-910616.html" target="_blank">For live updates of the coronavirus outbreak, click here</a></strong></p>.<p>"We are at the forefront of targeting the innate immune system through novel NLRP3 inflammasome inhibitors candidates with a deep understanding of the inflammasome biology," Cadila Healthcare Chairman Pankaj R Patel said.</p>.<p>ZYIL1 has demonstrated promising efficacy in a number of validated preclinical models of Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS), Sepsis and acute lung injury models of Acute Respiratory Distress Syndrome (ARDS), Zydus Cadila said.</p>.<p>The company has completed all IND enabling preclinical studies and has filed the IND application to advance this drug candidate towards the clinic, it added.</p>.<p>Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 438.60 per scrip on BSE, up 6.94 per cent from its previous close.</p>